KOL Identification

A large multi-national diagnostic company was interested in understanding the market landscape and potential strategy for the decentralization of NIPT in the U.S.

A diagnostics player wanted to determine with indications / use cases to target and develop a product road map

A large pharma new to precision oncology wanted to understand the processes and requirements to ensure that their novel CDx was included into diagnostic guidelines globally

A top-10 biopharma wanted to assess how the biomarker testing and treatment landscape would change, and the potential impact on the use of their drug, in response to a recent approval of a new competing cancer therapy approved in earlier lines of treatment

A healthcare technology startup wanted to conduct an assessment of potential go-to-market strategies for their AI analytical patient recruitment tool

A large pharmaceutical company engaged DeciBio to evaluate strategies for an internal build of a lab to support clinical and commercial opportunities in oncology